Herausragende Publikationen
2017
Phosphorylation of SOS1 on tyrosine 1196 promotes its RAC GEF activity and contributes to BCR-ABL leukemogenesis.
Gerboth S, Frittoli E, Palamidessi A, Baltanas FC, Mogjiborahman S, Rappsilber J, Giuliani C, Troglio F, Rolland Y, Pruneri G, Kreutmair S, Pallavicini I, Zobel M, Cinquanta M, Minucci S, Gomez C, Santos E, Illert AL, Scita G.
Leukemia. 2017 Aug 18. doi: 10.1038/leu.2017.267.
www.ncbi.nlm.nih.gov/pubmed/28819285
Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial
Jürgen Finke, Claudia Schmoor, Wolfgang Andreas Bethge, Hellmut Ottinger, Matthias Stelljes, Liisa Volin, Dominik Heim, Hartmut Bertz,Olga Grishina, Gerard Socie
Lancet Haematol 2017;4: e293–301
Full text
Comment | Frédéric Baron
Unrelated donor haemopoietic stem-cell transplantation: ATG or not?
High-throughput sequencing for noninvasive disease detection in hematologic malignancies
Florian Scherer, David M. Kurtz, Maximilian Diehn and Ash A. Alizadeh
Blood 2017 :blood-2017-03-735639; doi:
Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice.
Harlander S, Schönenberger D, Toussaint NC, Prummer M, Catalano A, Brandt L, Moch H, Wild PJ, Frew IJ.
Nature Medicine. 2017 May 29. doi: 10.1038/nm.4343. [Epub ahead of print]
MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT-signaling in dendritic cells after stem cell transplantation.
Stickel N, Hanke K, Marschner D, Prinz G, Köhler M, Melchinger W, Pfeifer D, Schmitt-Graeff A, Brummer T, Heine A, Brossart P, Wolf D, von Bubnoff N, Finke J, Duyster J, Ferrara J, Salzer U, Zeiser R.
Leukemia (9 May 2017) | doi:10.1038/leu.2017.137
New Paper by Rouven Hoefflin et al.
- Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity
Rouven Hoefflin, Bernd Lahrmann, Gregor Warsow, Daniel Hübschmann, Cathleen Spath, Britta Walter, Xin Chen, Luisa Hofer, Stephan Macher-Goeppinger, Yanis Tolstov, Nina Korzeniewski, Anette Duensing, Carsten Grüllich, Dirk Jäger, Sven Perner, Gita Schönberg, Joanne Nyarangi-Dix, Sanjay Isaac, Gencay Hatiboglu, Dogu Teber et al.
Nature Communications 7, Article number: ncomms11845doi:10.1038/ncomms11845 | Received 21 January 2016 | Accepted 04 May 2016 | Published 13 June 2016
==> http://www.nature.com/articles/ncomms11845
Cover image, Blood, April 14, 2016
Publikation AG Zeiser | April 14, 2016; Blood
The Journal of Experimental Medicine
New Paper by PD Dr. Christine Dierks und Team:
Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression. ⇒
Klein C, Zwick A, Kissel S, Forster CU, Pfeifer D, Follo M, Illert AL,Decker S, Benkler T, Pahl H, Oostendorp RA, Aumann K, Duyster J,Dierks C.
J Exp Med. 2016 Feb 8;213(2):273-90. doi: 10.1084/jem.20150556. Epub2016 Feb 1.
ASBMT eNews
Ruxolitinib is Potential Corticosteroid-Refractory GVHD Therapy [PDF]
Original Article ↓
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Leukemia (2015) 29, 2062–2068; doi:10.1038/leu.2015.212;
2015
Neues GvHD Behandlungs Konzept aus Freiburg
Prof. Zeiser/Prof. von Bubnoff
